CAITLIN PITECK: Open Payments
NPI 1528749124 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,905 in 71 payments from 29 companies in 2025. Trend: 2023 $685 · 2024 $2,244 · 2025 $1,905
Food & beverage: $1,905
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $217 |
| AstraZeneca Pharmaceuticals LP | 6 | $175 |
| GlaxoSmithKline, LLC. | 6 | $161 |
| Amgen Inc. | 2 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $145 |
| ViiV Healthcare Company | 1 | $138 |
| Exact Sciences Corporation | 4 | $112 |
| Lilly USA, LLC | 4 | $80 |
| GENZYME CORPORATION | 2 | $79 |
| Gilead Sciences, Inc. | 2 | $60 |
Products named: APRETUDE, XIFAXAN, FARXIGA, Cologuard Collection Kit, TRELEGY ELLIPTA, Rybelsus, DUPIXENT, SPRAVATO.
Industry payments across CA — which companies pay providers there.
